Breaking Finance News

finnCap disclosed Synairgen PLC (LON:SNG), retaining its price target at 137.00GBX earlier today

Having a price of 34.50GBX, Synairgen PLC (LON:SNG) traded -2.90% lower on the day. With the last close up 11.27% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SNG has recorded a 50-day average of 34.30GBX and a two hundred day average of 30.11GBX. Trading volume was down over the average, with 6,004 shares of SNG changing hands under the typical 43,164

Reporting as potential upside of 2.97%, finnCap hold steady the price target of Synairgen PLC (LON:SNG) at 137.00GBX

On 8/30/2016, finnCap released a statement on Synairgen PLC (LON:SNG) maintained the target price at 137.00GBX that suggested an upside of 0%.

Performance Chart

Synairgen PLC (LON:SNG)

With a total market value of 0 GBX, Synairgen PLC has with a one year low of 19.00GBX and a one year high of 38.00GBX .

A total of 2 brokers have issued a research note on SNG. 0 firms rating the stock a strong buy, one analyst rating the stock a buy, 0 brokerages rating the company a hold, zero brokers rating the stock a underperform, and finally zero equity analysts rating the company a sell with a consensus target price of 87.00GBX.

About Synairgen PLC (LON:SNG)

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.